SEOUL, SOUTH KOREA (AP) – Health officials in South Korea yesterday approved the country’s first domestically developed COVID-19 vaccine for people 18 years or older, adding another public health tool in the fight against a prolonged pandemic.
In clinical trials involving some 4,000 participants in South Korea and five other countries, SK Bioscience’s two-dose SKYCovione vaccine appeared to be more effective than the broadly used AstraZeneca shots in building immunity against infections, officials at South Korea’s Food and Drug Safety Ministry said.
It isn’t immediately clear how officials will administer the newly developed vaccine or how big of a role the shots will have in the next phase of the pandemic.
United States (US) vaccine giants Pfizer and Moderna have been speeding up their development of booster shots targetting Omicron and experts said it’s possible the virus could evolve again in the coming months.
South Korea’s mass immunisation campaign has been mainly dependent on Pfizer and Moderna’s mRNA shots. But officials said protein vaccines like SKYCovione, which are similar to shots used for years against the common flu and hepatitis B, could appeal to people who are hesitant to use vaccines developed with newer technologies. “The approval (of SKYCovione) internationally confirms the abilities of our companies to develop COVID-19 vaccines,” Food and Drug Safety Minister Oh Yu-kyoung said in a briefing.
She said SK Bioscience is seeking an approval from the World Health Organization (WHO) for its shots, which would potentially open export opportunities.
South Korea has eased most of its virus restrictions after battling an Omicron surge earlier this year, but some experts said the country may see another rise in infections despite a high vaccination rate because of waning immunities and the possible emergence of new variants.
The country reported 10,463 new cases of the coronavirus yesterday, its first daily increase over 10,000 in 20 days. Health Ministry official Son Youngrae said during a separate briefing it’s too early to tell whether the country is facing another surge after a months-long downward trend.